ABsTRAcr The effects of sodium cromoglycate and ketotifen were studied in a group of 20 patients in whom fish repeatedly provoked an attack of wheezing and dyspnoea within one hour of its being eaten. Fish ingestion resulted in a fall in forced expiratory volume in one second (FEV) 
different days. Cromoglycate blocked the fall in FEV, either completely or significantly in 16 patients. Ketotifen did not appear to have any significant effect in the group as a whole.
Food allergy has been a contentious subject for almost as long as it has been recognised as a clinical entity. It has sometimes been diagnosed without objective criteria and at times ignored despite strong clinical suggestion. '- ' 2 Recognition of an association is perhaps more difficult when the reaction is delayed. All the patients studied in this group had "immediate" asthmatic reactions to challenge with fish and often had other symptoms, including rhinorrhoea, itching sensations in the roof of the mouth and back of throat, perioral and periorbital swellings, and urticaria. Ingestion of fish consistently and repeatedly provoked airflow obstruction detected by significant falls in the FEV,. The double-blind administration of placebos did not prevent the onset of an asthmatic attack but cromoglycate often did.
Only four patients (Nos 7, 11, 12, and 16) had normal total serum IgE levels and in four others (Nos 3, 5, 10, and 19) the levels were over 1000 IU/ml. All patients had positive skin reactions to the pollen allergens tested. The four patients with greatly increased levels of serum IgE had strongly positive skin reactions to a wider variety of allergens. In three of the four patients in whom sodium cromoglycate failed to protect against fish challenge the total serum IgE level was very high (>1200 IU/ml). It has previously been shown in mite-sensitive asthmatic patients after challenge with aeroallergens that cromoglycate tends to be less effective in patients with high total IgE or allergenspecific IgE levels.'3 In the present group of patients serum IgA levels were low in four (Nos 9, 12, 15, and 20), all of whom were protected by cromoglycate. Persistently low levels of IgA have been associated with an increased incidence of allergy. '4 This may be due to a failure of IgA to prevent interactions between antigens and cell-bound IgE, IgG, or IgM at the mucosal level. The possibility that impaired antigen exclusion by the intestinal mucosa may have a role in the development of food allergy by increasing the risk of immunisation with antigens is further supported by the fact that there is a considerably increased incidence of antibodies to dietary proteins in IgA deficiency. '5 The mode of action of sodium cromoglycate remains uncertain. '6 '7 In food allergy sodium cromoglycate probably prevents mediator release from superficial mast cells in the gastrointestinal tract, thereby reducing gut permeability. In several well-documented studies sodium cromoglycate has been shown to cause decreased entry of antigen through the gut and diminished immune-complex formation and to prevent atopic symptoms. '8-20 Ketotifen, a benzocycloheptathiophene, is said to be an orally active compound with mast-cell stabilising and antihistaminic properties, 2' and against fish challenge. This may be due to the fact that the drug was given for only three days before challenge. It has, however, been reported that similar treatment periods28 and even single 2-mg doses of ketotifen29 protect asthmatic patients against challenge with specific allergen. Maximum serum drug concentrations are reached only three hours after oral administration of 2 mg ketotifen and in this study the final dose was given half an hour before challenge; but adequate drug concentrations (1-2 ng/ml) are known to be achieved when the drug is given in doses of 1 mg twice daily. 30 The real role of ketotifen in the management of asthma requires further study.
